Kathryn E. Marqueen

Kathryn E. Marqueen

Auto-generated profile, based on publicly available information

Kathryn E. Marqueen

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2021 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
KMKathryn E. Marqueen
Kathryn E. Marqueen
EMErin Moshier
Erin Moshier
MBMichael Buckstein
Michael Buckstein
CACelina Ang
Celina Ang

4 June 2021 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
ALAnna Lee
Anna Lee
JKJung J. Kang
Jung J. Kang
HBHavah Bernstein
Havah Bernstein
KMKathryn E. Marqueen
Kathryn E. Marqueen
BNBrian Neal
Brian Neal
Nancy LeeNancy Lee
Nancy Lee
Patients with previously treated, recurrent or metastatic sarcomas who have progressed on multiples lines of systemic therapy may have limited options for local control. We evaluated outcomes of palliative proton therapy with the quad shot regimen to unresectable disease for patients with recurrent and/or metastatic sarcoma. From 2014 to 2018, 28 patients with recurrent or metastatic sarcomas were treated to 40 total sites with palliative proton RT with quad shot (14.8 Gy/4 twice daily). Outcomes included toxicity, ability to receive further systemic therapy, and subjective palliative response. Univariate analysis was performed for local progression‐free survival (LPFS) and overall survival (OS). Of the 40 total sites, 25 (62.5%) received ≥3 cycles with median follow up of 12 months (IQR 4–19). The most common histologies were GIST (9; 22.5%) and leiomyosarcoma (7; 17.5%). A total of 27 (67.5%) sites were located in the abdomen or pelvis. Seventeen (42.5%) treatments involved concurrent systemic therapy and 13 (32.5%) patients received further systemic therapy following proton therapy. Overall subjective palliative response was 70%. Median LPFS was 11 months and 6‐month LPFS was 66.1%. On univariate analysis, receipt of four cycles of quad shot (HR 0.06, p = 0.02) and receipt of systemic therapy after completion of radiation therapy (HR 0.17, p = 0.02) were associated with improved LPFS. Three grade 3 acute toxicities were observed. The proton quad shot regimen serves as a feasible alternative for patients with previously treated, recurrent or metastatic sarcomas where overall treatment options may be limited.

1 June 2025 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
PSPaul W. Sperduto
Paul W. Sperduto
KMKathryn E. Marqueen
Kathryn E. Marqueen
ECEnoch Chang
Enoch Chang
JLJing Li
Jing Li
MDMichael A Davies
Michael A Davies
MMMinesh p Mehta
Minesh p Mehta
PURPOSE: Survival for patients with melanoma has recently improved. The propensity of melanoma to metastasize to the brain remains a common and serious feature of this disease. The purposes of this study were to evaluate prognostic factors for patients with newly diagnosed melanoma brain metastases (MBMs) in a large cohort treated with modern multimodal therapies, compare those results with those in prior eras, and update the Melanoma Graded Prognostic Assessment (GPA). METHODS: Univariable and multivariable (MVA) analyses of prognostic factors and treatments associated with survival were performed on 1,796 patients with newly diagnosed MBM treated between January 01, 2015, and December 31, 2021, using a multi-institutional retrospective database. Multiple imputation was used to address missingness of potential predictors. Significant variables in combined MVA were used to update the Melanoma GPA. Comparisons were made with legacy cohorts. RESULTS: Median survivals for cohorts A (1985-2007, n = 481), B (2006-2015, n = 823), and C (2015-2021, n = 1,796) were 6.7, 9.8, and 16.6 months and median follow-up times were 40.1, 43.6, and 48.8 months, respectively. In combined MVA, significant prognostic factors for survival were higher Karnofsky Performance Status, fewer MBMs, absence of extracranial metastases, lower serum lactate dehydrogenase, and no immunotherapy before MBM. These factors were incorporated into the updated Melanoma GPA. The combined median and 3-year survivals for patients with GPA 0-1, 1.5-2, and 2.5-4.0 were 5.4, 13.2, and 43.2 months and 12.4%, 28.8%, and 51.6%, respectively. CONCLUSION: Prognostic factors have changed and survival has improved for patients with MBM but varies widely by GPA. The updated Melanoma GPA calculator (BrainMetGPA), available free online, can be used to estimate survival, individualize treatment, stratify clinical trials, guide surveillance, and augment clinical trial eligibility. Multidisciplinary treatment is essential. Trials are needed to elucidate the optimal sequencing of various therapeutic modalities.

12 April 2021 in Cancer
Verified
Journal Article
Closed access
PDF file
AEAntoine Eskander
Antoine Eskander
KMKathryn E. Marqueen
Kathryn E. Marqueen
HEHeather A. Edwards
Heather A. Edwards
AJAnthony M. Joshua
Anthony M. Joshua
TPTeresa M. Petrella
Teresa M. Petrella
BFBart S. Ferket
Bart S. Ferket

1 November 2023 in Practical Radiation Oncology
Verified
Journal Article
Open access
AYAlison Yoder
Alison Yoder
TXTianlin Xu
Tianlin Xu
PYPeter Youssef
Peter Youssef
SDSarah DeSnyder
Sarah DeSnyder
KMKathryn E. Marqueen
Kathryn E. Marqueen
SSSimona F. Shaitelman
Simona F. Shaitelman
Dermal backflow visualized on near-infrared fluorescence lymphatic imaging (NIRF-LI) signals preclinical lymphedema that precedes the development of volumetrically defined lymphedema. We sought to evaluate whether dermal backflow correlates with patient-reported lymphedema outcomes (PRLO) surveys in breast cancer patients treated with regional nodal irradiation (RNI). Patients with breast cancer planned for axillary dissection and RNI prospectively underwent perometry, NIRF-LI, and PRLOs (the Lymphedema Symptom Intensity and Distress Survey [LSIDS] and QuickDASH) at baseline, after surgery, and at 6, 12, and 18 months after radiation. Clinical lymphedema was defined as an arm volume increase ≥5% over baseline. Trends over time were assessed using analysis of variance testing. The association between survey responses and both dermal backflow and lymphedema was assessed using a linear mixed-effects model. Sixty participants completed at least 2 sets of measurements and surveys and were eligible for analysis. Fifty-four percent of patients had cT3-T4 disease, 53% cN3 disease, and 75% had a body mass index >25. Dermal backflow and clinical lymphedema increased from 10% to 85% and from 0% to 40%, respectively, from baseline to 18 months. In the adjusted model, soft tissue sensation, neurologic sensation, and functional LSIDS subscale scores were associated with presence of dermal backflow (all P < .05). Both dermal backflow and lymphedema were associated with QuickDASH score (P < .05). In this high-risk cohort, we found highly prevalent early signs of lymphedema, with increased symptom burden from baseline. Presence of dermal backflow correlated with PRLO measures, highlighting a potential NIRF-LI use to identify patients for early intervention trials after RNI.

20 November 2025 in Brachytherapy
Verified
Journal Article
Closed access
KMKathryn E. Marqueen
Kathryn E. Marqueen
KCKelsey L. Corrigan
Kelsey L. Corrigan
SPSurendra Prajapati
Surendra Prajapati
RKRajat J. Kudchadker
Rajat J. Kudchadker
GMGohar Shahwar Manzar
Gohar Shahwar Manzar
SFSteven J Frank
Steven J Frank